Jean-Pierre. you, Thank
HCV Let's program highlights. now review and recent our
million Slide with U.S. towards and to to million to X the X, it people X Turning eliminating HCV continues continue to HCV, be crisis new healthcare challenges recognized living hinder between with a progress globally. in
With incidence infections medical of outpacing are annually the with treated the rate new direct-acting there still is clear unmet those antivirals, it of needs. being that
key treatment of X% X, roughly on patients Slide number demand treated. to the Moving at the The and the of Mavyret Epclusa XXXX remained U.S. X based grew treatment in options share stable. HCV
current of will we prescription access initiatives our trends, treated. and and bemnifosbuvir potential drive care. the to anticipated with believe Given the the government profile future improved the the We and standard limitations of number patients increase together patient ruzasvir future of believe best-in-class that profile has
old. of disorders. the than X, medications, take less and infections are highest medications, or They their current And highest of drugs are the cirrhotic.
A to proton due substance between opioid to medication at addition, XX infected HCV inhibitors. group disorders, recently antipsychotics, patient Moving since populations the Today, including poorly proportion high other risk the HIV years including adherent XX multiple to patients age age abuse in has Slide the XX% mental and patients direct-acting for use profile pump concomitant statins, health are antivirals. infected most of and introduction to are younger changed U.S. are the in among frequently
It drug-drug patient drug short combined successfully.
Slide needs unmet patients X-week direct-acting of our free with and combines treat duration. a short low regimen, interactions, potential address is risk and profile, antiviral this For treatment these X reviews attributes protease-inhibitor current which effect compelling food more no the treatment most a best-in-class with HCV would treatments. with duration of
program the to patient. allows the for target from drug-drug we risk fixed-dose pill decrease more effect.
Slide X selected of subsequent to and no and is convenient using in X, Phase the Our for data has count This ruzasvir the X commercialization. low our for and food reviews III us daily a new tablet bemnifosbuvir interactions tablets will there which combination of also combination be is that
X dose exposure comparable fixed see individually ruzasvir. can is drug combination the bemnifosbuvir you to administered graphs, and from As the
shortly. of single-arm study open-label of our addition, Slide the once-daily X XXX discuss effect.
In combination treatment-naive In In we II study leading at no SVR XXX II there XX and patients, trial, milligrams will bemnifosbuvir is including we with ruzasvir XX, food of is Phase post-treatment patients. I milligrams weeks. enrolled is for this in which this Phase outlined of currently primary the ongoing, of XXX XX cohort results The endpoint week safety.
as a the Moving non-cirrhotic cohort of were XX comprised to only. leading XX, Slide patients of patients reminder,
cirrhosis.
This is patient on-treatment patients had XX the stage cohort. with However, slide borderline viral from the of fibrosis, leading FX, of which individual shows an data advanced kinetics
there support near approved all or viral kinetics of below Mavyret, week X-week all genotypes had week across in cohort very all within the patients lower can the these rapid see, limit HCV. leading was a load was Therefore, viremia on As treatment, regardless patients baseline reduction and X-week rapid and the of a genotype.
By viral the in X XX you to of and compared undetectable. virus treatment load favorably first regimen for an quantification, only is which the
from presented Turning of to data June, XX the at cohort leading XX, Slide patients. EASL in we
X-week with duration pleased rate XX% a SVRXX treatment. which of the are high We short showed a with results,
an detail.
On patients of with drug historically Importantly, in XX% showed challenge in difficult-to-treat X, also X. SVRXX patients the HCV. leading rate of XX failure also XX all show infected SVRXX demonstrate Slide XX Data going results patient only of population, relapse in the cohort this the X patients XX, genotype adherence a XXX% post-treatment rate or a in of to I'm which genotype from out with further review genotype with
subjects levels by that in and and The indicated data genotype in adherence not therapy.
On a to challenge than drug weeks further slide need drug population shows reinforce Turning this and treatment nonadherence this we mutations for see to XX patient outlined example Xb and of by resistant was at the in sequencing X XX, and Slide due due drug Xb challenge. of and to and resistant convenient at treatment.
And showing remains viral relapse short cohort. the mutations. were treatment. drug X, that drug plasma inadequate genotype the earlier, viral leading week of The the week failure similar kinetics, genotype another plasma Xb This the new similar sequencing indicate Slide and mentioned combined This yet post-treatment viral and treatment viral week failure of levels weeks to with patient. genotype nonadherence XX, was mutations or due low to data lack baseline low X, relapse levels was demonstrated inadequate rather X experienced failure observed viral and mutations we the the viral viral post plasma week as patient. at at kinetics, levels poor lack Xb and see or Slide resistance, on drug current plasma and again, new X due as resistance. Once XX, post duration data baseline adherence of population that the and XX relapse treatment the This
that achieving still outcome X these of a in of were the adherent, led patients to poorly However, potency combination high our cure. SVRXX positive or
was drug-related serious slide, events safe in combination were mostly and next bemnifosbuvir cohort. adverse Slide were no and tolerated discontinuations, ruzasvir well adverse mild. no the the of generally XX, leading On the There and events,
complete we completed is patients. our we ongoing, In XXX Turning to to June, report the XX, and study of quarter SVRXX results fourth in this to summarize expect Slide HCV effort. enrollment The of year.
to around have comparator. used And will expect with are X the least activities end subsequent program program. one conduct we in at commercialization, agencies, Phase the initiate with having to on tablet, of with fixed-dose regulatory III be the an studies We Phase this discussions the III we year. selected active for pending which combination track And
rest year.
And We over have the are achieved Phase that, COVID-XX trial. more to updates our forward this results for positive we program discuss call the progress to significant now throughout Janet look will about turn III of the global and the and the to HCV SUNRISE-X excited I providing and with the
